- Home
- EDSA vs BCTX Comparison
EDSA vs BCTX Comparison
Compare EDSA & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- BCTX
- Stock Information
- Founded
- EDSA 2015
- BCTX 2014
- Country
- EDSA Canada
- BCTX Canada
- Employees
- EDSA N/A
- BCTX N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- BCTX Health Care
- Exchange
- EDSA Nasdaq
- BCTX Nasdaq
- Market Cap
- EDSA 17.2M
- BCTX 14.2M
- IPO Year
- EDSA N/A
- BCTX N/A
- Fundamental
- Price
- EDSA $2.39
- BCTX $8.64
- Analyst Decision
- EDSA Strong Buy
- BCTX Strong Buy
- Analyst Count
- EDSA 2
- BCTX 1
- Target Price
- EDSA $13.00
- BCTX $40.00
- AVG Volume (30 Days)
- EDSA 11.7K
- BCTX 84.7K
- Earning Date
- EDSA 08-08-2025
- BCTX 10-28-2025
- Dividend Yield
- EDSA N/A
- BCTX N/A
- EPS Growth
- EDSA N/A
- BCTX N/A
- EPS
- EDSA N/A
- BCTX N/A
- Revenue
- EDSA N/A
- BCTX N/A
- Revenue This Year
- EDSA N/A
- BCTX N/A
- Revenue Next Year
- EDSA N/A
- BCTX N/A
- P/E Ratio
- EDSA N/A
- BCTX N/A
- Revenue Growth
- EDSA N/A
- BCTX N/A
- 52 Week Low
- EDSA $1.55
- BCTX $6.00
- 52 Week High
- EDSA $5.00
- BCTX $214.50
- Technical
- Relative Strength Index (RSI)
- EDSA 51.55
- BCTX 51.22
- Support Level
- EDSA $2.41
- BCTX $7.93
- Resistance Level
- EDSA $2.47
- BCTX $8.20
- Average True Range (ATR)
- EDSA 0.09
- BCTX 0.48
- MACD
- EDSA -0.01
- BCTX 0.33
- Stochastic Oscillator
- EDSA 48.15
- BCTX 66.34
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.